Prevention of K-Ras- and Pten-mediated intravaginal tumors by treatment with camptothecin-loaded PLGA nanoparticles

Drug Delivery and Translational Research

Volumn 1, Issue 5, 2011, Pages 383-394

  Blum, Jeremy S ^a   Weller, Caroline E ^a   Booth, Carmen J ^b   Babar, Imran A ^c   Liang, Xianping ^c   Slack, Frank J ^c   Saltzman, W Mark ^a  

^a Yale University   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c YALE UNIVERSITY   (United States)

Author keywords

Camptothecin; Drug delivery; Inducible tumor model; KRAS; Polymer nanoparticles; PTEN; Vaginal squamous cell carcinoma

Indexed keywords

BETA GALACTOSIDASE; CAMPTOTHECIN; CRE RECOMBINASE; DNA; NANOPARTICLE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; POLYGLACTIN;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS; DNA SEQUENCE; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG SOLUBILITY; FEMALE; GENE TRANSFER; GENOTYPE; GROWTH INHIBITION; HISTOPATHOLOGY; MOUSE; NONHUMAN; ONCOGENE K RAS; PARTICLE SIZE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; SCANNING ELECTRON MICROSCOPY; SQUAMOUS CELL CARCINOMA; TUMOR GROWTH; TUMOR MODEL; TUMOR SUPPRESSOR GENE; UTERUS; VAGINA; VAGINA CARCINOMA; VAGINA TUMOR; VIRUS RECOMBINANT;

EID: 84862985543     PISSN: 2190393X     EISSN: 21903948     Source Type: Journal    
DOI: 10.1007/s13346-011-0038-y     Document Type: Article

References (48)

1. Frank S, Jhingran A, Levenback C, Eifel P. Definitive radiation therapy for squamous cell carcinoma of the vagina. International Journal of Radiation Oncology. 2005; 62(1): 138-47. doi: 10. 1016/j. ijrobp. 2004. 09. 032.
2. Sankaranarayanan R, Ferlay J. Worldwide burden of gynaecological cancer: the size of the problem. Best Practice & Research Clinical Obstetrics & Gynaecology. 2006; 20(2): 207-25. doi: 10. 1016/j. bpobgyn. 2005. 10. 007.
3. Cancer Facts and Figures 2010. Atlanta, GA: American Cancer Society2010.
4. Tjalma W. The role of surgery in invasive squamous carcinoma of the vagina. Gynecol Oncol. 2001; 81(3): 360-5. doi: 10. 1006/gyno. 2001. 6171.
5. Creasman WT, Phillips JL, Menck HR. The national cancer data base report on cancer of the vagina. Cancer. 1998; 83(5): 1033-40.
6. Vaginal Cancer. In: Society AC, editor. Atlanta, GA: American Cancer Society; 2010.
7. Dixit S, Singhal S, Baboo HA. Squamous cell carcinoma of the vagina: a review of 70 cases. Gynecol Oncol. 1993; 48: 80-7.
8. Buck HW, Guth KJ. Treatment of vaginal intraepithelial neoplasia (primarily low grade) with iniquimod 5% cream. Journal of Lower Genital Tract Disease. 2003; 7(3): 290-3.
9. Haidopoulos D, Diakomanolis E, Rodolakis A, Vlachos G, Elsheikh A, Michalas S. Safety and efficacy of locally applied imiquimod cream 5% for the treatment of condylomata acuminata of the vulva. Arch Gynecol Obstet. 2003; 270(4): 240-3. doi: 10. 1007/s00404-003-0559-9.
10. Martin-Garcia RF. Imiquimod: an effective alternative for the treatment of invasive cutaneous squamous cell carcinoma. Dermatol Surg. 2005; 31: 371-4.
11. Ondo A, Mings S, Pestak R, Shanler S. Topical combination therapy for cutaneous squamous cell carcinoma in situ with 5-fluorouracil cream and imiquimod cream in patients who have failed topical monotherapy. J Am Acad Dermatol. 2006; 55(6): 1092-4. doi: 10. 1016/j. jaad. 2006. 06. 031.
12. Murta EFC, Neves Junior MA, Sempionato LRF, Costa MC, Maluf PJ. Vaginal intraepithelial neoplasia: clinical-therapeutic analysis of 33 cases. Arch Gynecol Obstet. 2005; 272(4): 261-4. doi: 10. 1007/s00404-005-0022-1.
13. Krebs HB, Helmkamp BF. Chronic ulcerations following topical therapy with 5-fluorouracil for vaginal human papillomavirus-associated lesions. Obstet Gynecol. 1991; 78(2): 205-8.
14. Venuti A, Massa S, Mett V, Vedova LD, Paolini F, Franconi R, et al. An E7-based therapeutic vaccine protects mice against HPV16 associated cancer. Vaccine. 2009; 27(25-26): 3395-7. doi: 10. 1016/j. vaccine. 2009. 01. 068.
15. Han L, Wang W, Fang Y, Feng Z, Liao S, Li W, et al. Soluble B and T lymphocyte attenuator possesses antitumor effects and facilitates heat shock protein 70 vaccine-triggered antitumor immunity against a murine TC-1 cervical cancer model in vivo. J Immunol. 2009; 183(12): 7842-50. doi: 10. 4049/jimmunol. 0804379.
16. Decrausaz L, Gonçalves A-R, Domingos-Pereira S, Pythoud C, Stehle J-C, Schiller J, et al. A novel mucosal orthotopic murine model of human papillomavirus-associated genital cancers. International Journal of Cancer. 2010. doi: 10. 1002/ijc. 25561.
17. Daikoku T, Hirota Y, Tranguch S, Joshi AR, DeMayo FJ, Lydon JP, et al. Conditional loss of uterine Pten unfailingly and rapidly induces endometrial cancer in mice. Cancer Research. 2008; 68(14): 5619-27. doi: 10. 1158/0008-5472. can-08-1274.
18. Soyal SM, Mukherjee A, Lee KYS, Li J, Li H, DeMayo FJ, et al. Cre-mediated recombination in cell lineages that express the progesterone receptor. Genesis. 2005; 41(2): 58-66. doi: 10. 1002/gene. 20098.
19. Dinulescu DM, Ince TA, Quade BJ, Shafer SA, Crowley D, Jacks T. Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nature Medicine. 2005; 11(1): 63-70.
20. O'Leary J, Muggia FM. Camptothecins: a review of their development and schedules of administration. European Journal of Cancer. 1998; 34(10): 1500-8.
21. Wall ME, Wani MC, Cook CE, Palmer KH, McPhail AT, Sim GA. Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J Am Chem Soc. 1966; 88(16): 3888-90.
22. Wall ME, Wani MC. Camptothecin and taxol: from discovery to clinic. J Ethnopharmacol. 1996; 51: 239-54.
23. Slichenmyer WJ, Rowinsky EK, Donehower RC, Kaufmann SH. The current status of camptothecin analogues as antitumor agents. Journal of the National Cancer Institute. 1993; 85: 271-91.
24. Ertl B, Platzer P, Wirth M, Gabor F. Poly(D, L-lactic-co-glycolic acid) microspheres for sustained delivery and stabilization of camptothecin. Journal of Controlled Release. 1999; 61: 305-17.
25. Liu J, Jiang Z, Zhang S, Saltzman WM. Poly(ω-pentadecalactone-co-butylene-co-succinate) nanoparticles as biodegradable carriers for camptothecin delivery. Biomaterials. 2009; 30(29): 5707-19. doi: 10. 1016/j. biomaterials. 2009. 06. 061.
26. Sawyer AJ, Saucier-Sawyer JK, Booth CJ, Liu J, Patel T, Piepmeier JM, et al. Convection-enhanced delivery of camptothecin-loaded polymer nanoparticles for treatment of intracranial tumors. Drug Delivery and Translational Research. 2010; 1(1): 34-42. doi: 10. 1007/s13346-010-0001-3.
27. Woodrow KA, Cu Y, Booth CJ, Saucier-Sawyer JK, Wood MJ, Mark Saltzman W. Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small-interfering RNA. Nat Mater. 2009; 8(6): 526-33. doi: 10. 1038/nmat2444.
28. Jackson EL. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes & Development. 2001; 15(24): 3243-8. doi: 10. 1101/gad. 943001.
29. Lesche R, Groszer M, Gao J, Wang Y, Messing A, Sun H, et al. Cre/loxP-mediated inactivation of the murine Pten tumor suppressor gene. Genesis. 2002; 32(2): 148-9. doi: 10. 1002/gene. 10036.
30. G12D stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell. 2004; 5: 375-87.
31. Davis BJ, Dixon D, Herbet RA. Pathology of the Mouse. Vienna: Cache River Press; 1999.
32. Leslie NR, Downes CP. PTEN function: how normal cells control it and tumour cells lose it. Biochem J. 2004; 382: 1-11.
33. Elmasry K, Gayther S. Genetic mutations in gynaecological cancers. Reviews in Gynaecological and Perinatal Practice. 2006; 6(3-4): 115-25. doi: 10. 1016/j. rigapp. 2006. 05. 009.
34. Kim TH, Wang J, Lee KY, Franco HL, Broaddus RR, Lydon JP, et al. The synergistic effect of conditional Pten loss and oncogenic K-ras mutation on endometrial cancer development occurs via decreased progesterone receptor action. Journal of Oncology. 2010; 2010: 1-10. doi: 10. 1155/2010/139087.
35. G12D-induced pancreatic cancer development. Cancer Research. 2010; 70(18): 7114-24. doi: 10. 1158/0008-5472. can-10-1649.
36. Najbauer J, Yang Y, Iwanaga K, Raso MG, Wislez M, Hanna AE, et al. Phosphatidylinositol 3-kinase mediates bronchioalveolar stem cell expansion in mouse models of oncogenic K-ras-induced lung cancer. PLoS ONE. 2008; 3(5): e2220. doi: 10. 1371/journal. pone. 0002220.
37. Iwanaga K, Yang Y, Raso MG, Ma L, Hanna AE, Thilaganathan N, et al. Pten inactivation accelerates oncogenic K-ras-initiated tumorigenesis in a mouse model of lung cancer. Cancer Research. 2008; 68(4): 1119-27. doi: 10. 1158/0008-5472. can-07-3117.
38. Hildesheim A, Han CL, Brinton LA, Nasca PC, Richart RM, Jones RB, et al. Sexually transmitted agents and risk of carcinoma of the vagina. International Journal of Gynocologic Cancer. 1997; 7: 251-5.
39. Fuste V, del Pino M, Perez A, Garcia A, Torne A, Pahisa J, et al. Primary squamous cell carcinoma of the vagina: human papillomavirus detection, p16INK4A overexpression and clinicopathological correlations. Histopathology. 2010; 57(6): 907-16. doi: 10. 1111/j. 1365-2559. 2010. 03727. x.
40. Hellman K, Alaiya AA, Schedvins K, Steinberg W, Hellström AC, Auer G. Protein expression patterns in primary carcinoma of the vagina. British Journal of Cancer. 2004. doi: 10. 1038/sj. bjc. 6601944.
41. Hellman K, Silfversward C, Nilsson B, Hellstrom AC, Frankendal B, Pattersson F. Primary carcinoma of the vagina: factors influencing the age at diagnosis. The Radiumhemmet series 1956-96. International Journal of Gynocologic Cancer. 2004; 14: 491-501.
42. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ. 2010; 340: c3493. doi: 10. 1136/bmj. c3493.\
43. Patton TJ, Kavanagh JJ, Delclos L, Wallace S, Haynie TP, Wharton T, et al. Five-year survival in patients given intra-arterial chemotherapy prior to radiotherapy for advanced squamous carcinoma of the cervix and vagina. Gynecol Oncol. 1991; 42: 54-9.
44. Cone RA. Barrier properties of mucus. Advanced Drug Delivery Reviews. 2009; 61(2): 75-85. doi: 10. 1016/j. addr. 2008. 09. 008.
45. Lai SK, Wang YY, Hida K, Cone R, Hanes J. Nanoparticles reveal that human cervicovaginal mucus is riddled with pores larger than viruses. Proceedings of the National Academy of Sciences. 2009; 107(2): 598-603. doi: 10. 1073/pnas. 0911748107.
46. Cu Y, Saltzman WM. Mathematical modeling of molecular diffusion through mucus. Advanced Drug Delivery Reviews. 2009; 61(2): 101-14. doi: 10. 1016/j. addr. 2008. 09. 006.
47. Cu Y, Saltzman WM. Controlled surface modification with poly(ethylene)glycol enhances diffusion of plga nanoparticles in human cervical mucus. Mol Pharm. 2008; 6(1): 173-81.
48. Saltzman WM. Drug delivery: engineering principles for drug therapy. New York: Oxford University Press; 2001.